Evidence map›Paper›PMID 29386285›Full record

ArticleJournal of virology2018

Functional Optimization of Broadly Neutralizing HIV-1 Antibody 10E8 by Promotion of Membrane Interactions.

Edurne Rujas, Daniel P Leaman, Sara Insausti, Lei Ortigosa-Pascual, Lei Zhang, Michael B Zwick, José L Nieva

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Engineering pan-HIV-1 neutralization potency through multispecific antibody avidity.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Edurne Rujas *Biofisika Institute (CSIC, UPV/EHU), University of the Basque Country (UPV/EHU), Bilbao, Spain.
Daniel P Leaman *Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.
Sara InsaustiBiofisika Institute (CSIC, UPV/EHU), University of the Basque Country (UPV/EHU), Bilbao, Spain.
Lei Ortigosa-PascualBiofisika Institute (CSIC, UPV/EHU), University of the Basque Country (UPV/EHU), Bilbao, Spain.
Lei ZhangDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.
Michael B ZwickDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA zwick@scripps.edu joseluis.nieva@ehu.es.
José L NievaBiofisika Institute (CSIC, UPV/EHU), University of the Basque Country (UPV/EHU), Bilbao, Spain zwick@scripps.edu joseluis.nieva@ehu.es.
Biofisika · ESScripps Research Institute · USUniversity of the Basque Country · ES

Funding

Eliciting antibodies to probe native trimeric gp41 for HIV vaccine designR01AI114401 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ZWICK, MICHAEL B · 2014 to 2018
$2.9M
Selecting HIV recombination libraries for stable Env trimer immunogensR01AI098602 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ZWICK, MICHAEL B · 2012 to 2016
$2.6M
HIV-1 vaccine design emphasizing bnAb targets on membrane Env liposomesR56AI143563 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ZWICK, MICHAEL B · 2019 to 2019
$292k
NIAID NIH HHS R01 AI098602NIAID NIH HHS R01 AI114401NIAID NIH HHS R56 AI143563
6 · The paper itself

Abstract

The 10E8 antibody targets a helical epitope in the membrane-proximal external region (MPER) and transmembrane domain (TMD) of the envelope glycoprotein (Env) subunit gp41 and is among the broadest known neutralizing antibodies against HIV-1. Accordingly, this antibody and its mechanism of action valuably inform the design of effective vaccines and immunotherapies. 10E8 exhibits unusual adaptations to attain specific, high-affinity binding to the MPER at the viral membrane interface. Reversing the charge of the basic paratope surface (from net positive to net negative) reportedly lowered its neutralization potency. Here, we hypothesized that by increasing the net positive charge in similar polar surface patches, the neutralization potency of the antibody may be enhanced. We found that an increased positive charge at this paratope surface strengthened an electrostatic interaction between the antibody and lipid bilayers, enabling 10E8 to interact spontaneously with membranes. Notably, the modified 10E8 antibody did not gain any apparent polyreactivity and neutralized virus with a significantly greater potency. Binding analyses indicated that the optimized 10E8 antibody bound with a higher affinity to the epitope peptide anchored in lipid bilayers and to Env spikes on virions. Overall, our data provide a proof of principle for the rational optimization of 10E8 via manipulation of its interaction with the membrane element of its epitope. However, the observation that a similar mutation strategy did not affect the potency of the first-generation anti-MPER antibody 4E10 shows possible limitations of this principle. Altogether, our results emphasize the crucial role played by the viral membrane in the antigenicity of the MPER-TMD of HIV-1.

Indexed as

Antibodies, NeutralizingCell LineCell MembraneHIV-1HIV AntibodiesHIV Envelope Protein gp41HIV InfectionsHumansAntibodies, Neutralizinggp41 protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp4110E84E10anti-MPER antibodybroadly neutralizing antibodyhuman immunodeficiency virus

Identifiers

PMID29386285
PMCPMC5874428
OpenAlexW2792438776

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.